Evidence map›Paper›PMID 33587894›Full record

Trial reportThe Lancet. Oncology2021

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.

Mahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, Georgina V Long, Keith T Flaherty, Dirk Schadendorf, Paul D Nathan, Caroline Robert, Antoni Ribas, Michael A Davies and 7 more

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Lancet. Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06710093 (Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma), which is not on this map. Cited by 71 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06710093 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma

Typeobservational_patient_registrySponsorRoyal Marsden NHS Foundation TrustRan2025 to 2029Enrolled100ConditionsMetastatic Melanoma
3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Advances in laboratory medicine · 2025
    Article
  17. Advances in laboratory medicine · 2025
    Article
  18. Article
  19. Article
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 5 countries.

Mahrukh M SyedaNYU Langone Health, New York, NY, USA.
Jennifer M WigginsNYU Langone Health, New York, NY, USA.
Broderick C CorlessNYU Langone Health, New York, NY, USA.
Georgina V LongMelanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
Keith T FlahertyDana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.
Dirk SchadendorfUniversity Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.
Paul D NathanEast and North NHS Trust, Northwood, UK.
Caroline RobertInstitute Gustave Roussy and Paris-Sud University, Villejuif, France.
Antoni RibasDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jean Jacques GrobDermatology and Skin Cancer Department, Aix-Marseille University, Marseille, France.
Eduard GasalNovartis Pharmaceuticals, East Hanover, NJ, USA.
Matthew SquiresNovartis Institute for BioMedical Research, Cambridge, MA, USA.
Mahtab MarkerNovartis Pharmaceuticals, East Hanover, NJ, USA.
James GarrettNovartis Pharmaceuticals, Cambridge, MA, USA.
Jan C BraseNovartis Pharma, Basel, Switzerland.
David PolskyNYU Langone Health, New York, NY, USA. Electronic address: david.polsky@nyulangone.org.
Novartis (United States) · USNYU Langone Health · USAix-Marseille Université · FRDana-Farber Cancer Institute · USDeutschen Konsortium für Translationale Krebsforschung · DEMelanoma Institute Australia · AUNovartis (Switzerland) · CHThe University of Texas MD Anderson Cancer Center · USUniversité Paris-Sud · FRUniversity of California, Los Angeles · US

Funding

Cutaneous Biology and Skin Disease Training ProgramT32AR064184 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ORLOW, SETH J. · 2014 to 2024
$2.1M
Validation of circulating tumor DNA assays for detection of metastatic melanomaUH3CA206124 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI POLSKY, DAVID · 2018 to 2020
$1.4M
Validation of circulating tumor DNA assays for detection of metastatic melanomaUH2CA206124 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI POLSKY, DAVID · 2016 to 2017
$460k
NCI NIH HHS UH2 CA206124NCI NIH HHS UH3 CA206124NIAMS NIH HHS T32 AR064184
6 · The paper itself

Abstract

backgroundMelanoma lacks validated blood-based biomarkers for monitoring and predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising biomarker; however, various detection methods have been used, and, to date, no large studies have examined the association between serial changes in ctDNA and survival after BRAF, MEK, or BRAF plus MEK inhibitor therapy. We aimed to evaluate whether baseline ctDNA concentrations and kinetics could predict survival outcomes.

methodsIn this clinical validation study, we used analytically validated droplet digital PCR assays to measure BRAF

findingsIn COMBI-d, pretreatment plasma samples were available from 345 (82%) of 423 patients and on-treatment (week 4) plasma samples were available from 224 (53%) of 423 patients. In cohort A of COMBI-MB, pretreatment and on-treatment samples were available from 38 (50%) of 76 patients with intracranial and extracranial metastatic melanoma. ctDNA was detected in pretreatment samples from 320 (93%) of 345 patients (COMBI-d) and 34 (89%) of 38 patients (COMBI-MB). When assessed as a continuous variable, elevated baseline BRAF

interpretationPretreatment and on-treatment BRAF

fundingNovartis.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsCirculating Tumor DNADouble-Blind MethodFemaleFollow-Up StudiesHumansImidazolesMaleMelanomaMiddle AgedOximesPrognosisPyridonesPyrimidinonesCirculating Tumor DNAdabrafenibImidazolesOximesPyridonesPyrimidinonestrametinib

Identifiers

PMID33587894
PMCPMC8034833
OpenAlexW3131642700

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.